Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Arachidonate 5-lipoxygenase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus granulosus | arachidonate 5 lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Schistosoma japonicum | ko:K00461 arachidonate 5-lipoxygenase [EC1.13.11.34], putative | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Schistosoma mansoni | lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Schistosoma japonicum | IPR001024,Lipoxygenase, LH2;IPR013819,Lipoxygenase, C-terminal,domain-containing | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Schistosoma mansoni | lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Echinococcus multilocularis | arachidonate 5 lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0409 | 1 | 0.5 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0409 | 1 | 0.5 |
Echinococcus multilocularis | arachidonate 5 lipoxygenase | 0.0142 | 0.1385 | 0.5 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0409 | 1 | 0.5 |
Echinococcus granulosus | arachidonate 5 lipoxygenase | 0.0142 | 0.1385 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0409 | 1 | 0.5 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0409 | 1 | 0.5 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0409 | 1 | 0.5 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0409 | 1 | 0.5 |
Trichomonas vaginalis | hypothetical protein | 0.0409 | 1 | 0.5 |
Schistosoma mansoni | lipoxygenase | 0.0142 | 0.1385 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = -73 % | Inhibition of leukotriene formation in A-23,187-stimulated mouse whole blood using LTB4 specific RIA ex vivo, activity expressed as percent of control. | ChEMBL. | 8978834 |
Activity (functional) | = -73 % | Inhibition of leukotriene formation in A-23,187-stimulated mouse whole blood using LTB4 specific RIA ex vivo, activity expressed as percent of control. | ChEMBL. | 8978834 |
ED50 (functional) | = 9.8 mg kg-1 | Compound was tested to inhibit Leukotriene formation in A-23,187-stimulated mouse whole blood using LTB4 specific RIA ex vivo | ChEMBL. | 8978834 |
ED50 (functional) | = 9.8 mg kg-1 | Compound was tested to inhibit Leukotriene formation in A-23,187-stimulated mouse whole blood using LTB4 specific RIA ex vivo | ChEMBL. | 8978834 |
IC50 (binding) | = 2.7 uM | Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay. | ChEMBL. | 8978834 |
IC50 (binding) | = 2.7 uM | Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay. | ChEMBL. | 8978834 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.